



**Global Expert Network Conference on Innovations in
antimicrobial drug research and development**

Network conference on October 10th, 2016

at the Kempinski Hotel Bristol Berlin

Working group 1: Strategies to incentivize research and development of new
antibiotics and diagnostics

Room: *Gartensaal*

Full-day session

The current situation in the pharmaceutical market does not succeed in creating a stimulating environment for a vital developmental chain of new antimicrobial drugs and diagnostics. Additionally there is a need for more specialized experts for research in this field and a better coordination and networking of experts and research institutions. Consequently, there is a decline in innovative ways to identify and fight pathogens. This leads to a situation where the treatment of (drug resistant) microorganisms becomes more and more challenging. Therefore, this session aims to identify possible incentives (e.g. product development partnerships, easier approval procedures) to overcome this hurdle. The international experts from academia, national competent authorities, regulatory authorities, non-governmental organizations, pharma industries, health technology assessment and financing, funding agencies will discuss the respective advantages and disadvantages of the proposed approaches covering a broad spectrum of perspectives. An expected outcome of the session is to identify the most promising incentives for research and development of antimicrobial drugs and diagnostics.

9:00 – 9:30	Welcome coffee and registration
9:30 – 10:00	Welcome and opening session
Schloßsaal	Minister Hermann Gröhe, Federal Ministry of Health (BMG), Germany Federal Councillor Alain Berset, Federal Department of Home Affairs, Switzerland
10:00 – 10:10	Speaker
	Dr. Benjamin Grosch, Boston Consulting Group (BCG), Partner & Managing Director, Germany “ <i>GUARD initiative: Enhancing Research and Development of Antibiotics in Science and Industry</i> ”



Gartensaal	Working group 1: Strategies to incentivize research and development of new antibiotics and diagnostics
	Chair: Hala Audi, Head of the UK Review on AMR Team, UK
10:10 – 10:40	Speaker Prof. Dr. Tanja Schneider, University of Bonn, Germany <i>“Challenges in antibiotic discovery”</i>
10:40 – 11:10	Speaker Dr. Julie Gerberding, MSD, Executive Vice President & Chief Patient Officer, USA <i>“Sustainable models to overcome the challenging economics of antimicrobial discovery and development”</i>
11:10 – 11:40	Speaker Dr. Ursula Theuretzbacher, Center for Anti-Infective Agents (CEFAIA), Austria / DRIVE-AB partner <i>“Strengthening AMR R&D by coordination, cooperation and knowledge exchange”</i>
11:40 – 11:45	Coffee break
11:45 – 12:20	Speaker Yoshikazu Hayashi, Pharmaceutical and Medical Devices Agency (PMDA), Associate Center Director, Japan <i>“Ways to promote the development of new antimicrobials against AMR”</i>
12:20 – 1:00	Speaker Dr. Mair Powell, European Medicines Agency (EMA), Senior Clinical Assessor, UK <i>“Co-operation of National Competent Authorities and approval of new antibacterial agents”</i>
1:00 – 2:00	Lunch break
2:10 – 2:40	Speaker Dr. Peter Beyer, World Health Organization (WHO), Coordinator a.i., Switzerland <i>“Fostering research and development and stewardship for antibiotics”</i>
2:40 – 3:00	Coffee break
3:00 – 5:00	Statements and discussion Sibylle Matz, Federal Institute for Drugs and Medical Devices (BfArM), Head of Unit Antiinfectivs, Germany Dr. Marco Petschulies, Federal Joint Committee (G-BA), Scientific Advisor, Germany Dr. Joseph Larsen, Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), Acting Deputy Director of BARDA, USA Shiva Dustdar, European Investment Bank (EIB), Head of Division, Innovation Finance Advisory, Luxembourg Dr. Cuong Vuong, AiCuris Anti-infective Cures GmbH/BEAM Alliance, Germany
5:00 – 5:30	Closing remarks
Schloßsaal	Plenary session
5:30	End of session



Working group 2: Antibiotics and their use at the interface between human and veterinary medicine

Room: *Salon Charlottenburg & Salon Cecilienhof*

Full-day session

The improper application or overuse of antibiotics promotes the development of new antimicrobial resistances. As microorganisms are often transmitted between animals and humans this upcoming threat concerns not only human and veterinary medicine, but also food production, food supply and even environmental concerns.

The aim of working group 2 will therefore be to illustrate the current situation of antibiotic use at the interface between humans and animals and to analyze relevant consequences. The discussions will be stimulated by practical examples of innovative approaches for the prudent use of antibiotics, the prevention of infections or the implementation of effective surveillance systems. Rising opportunities of such innovative alternative methods shall be outlined in the discussion. Eventually, the experts will discuss the need for innovations in human and veterinary medicine.

The session will take the needs for effective and sufficient food supply with reasonable prices and the proper medical care for all kinds of domestic animals into account.

9:00 – 9:30	Welcome coffee and registration
9:30 – 10:00	Welcome and opening session
Schloßsaal	Minister Hermann Gröhe, Federal Ministry of Health (BMG), Germany Federal Councillor Alain Berset, Federal Department of Home Affairs, Switzerland
10:00 – 10:10	Speaker
	Dr. Benjamin Grosch, Boston Consulting Group (BCG), Partner & Managing Director, Germany <i>“GUARD initiative: Enhancing Research and Development of Antibiotics in Science and Industry”</i>
Charlottenburg & Cecilienhof	Working group 2: Antibiotics and their use at the interface between human and veterinary medicine
	Chair: PD Dr. Bernd-Alois Tenhagen, Federal Institute for Risk Assessment (BfR), Head of Unit, Germany
10:10 – 10:30	Speaker
	Dr. Tim Eckmanns, Robert Koch-Institute, Head of Unit, Germany <i>“Epidemiology of zoonotic pathogens and the transmission between humans and animals”</i>



10:30 – 10:50	Speaker Dr. Catharina Boehme, Foundation for Innovative New Diagnostics (FIND), Chief Executive Officer, Switzerland <i>“The role of diagnostics in the prevention and treatment of antimicrobial-resistant infections – a global health perspective”</i>
10:50 – 11:15	Speaker Prof. Dr. Yonghong Xiao, Zhejiang University, Principal Investigator, China <i>“AMR in China: From surveillance to epidemiology and molecular characters”</i>
11:15 – 11:40	Speaker Prof. Dr. Lothar Kreienbrock, University of Veterinary Medicine Hannover, Institute Director, Germany <i>“Use of antibiotics in farm animals in Germany”</i>
11:40 – 11:55	Coffee break
11:55 – 12:20	Speaker Dr. Matthew Stone, World Organization for Animal Health (O.I.E.), Director, New Zealand <i>“Perspective and activities of the OIE”</i>
12:20 – 1:00	Discussion
1:00 – 2:00	Lunch break
2:00 – 2:25	Speaker Dr. Karin Schwabenbauer, Federal Ministry of Food and Agriculture (BMEL) Chief Veterinary Officer, Germany <i>“The German antibiotics minimization concept”</i>
2:25 – 2:50	Speaker Dr. Merel Langelaar, Ministry of Health, Welfare and Sport, Netherlands <i>“Saving costs by antibiotic stewardship. Antibiotics at the interface of human and veterinary medicine: a One Health approach.”</i>
2:50 – 3:05	Coffee break
3:05 – 3:30	Speaker Dr. Christine Rohde, Phages for Human Applications Group Europe (P.H.A.G.E.), Germany <i>“Phages and their therapeutic potential”</i>
3:30 – 3:55	Speaker Dr. Hans Bundgaard, PORCUS swine veterinary consulting clinic, Denmark <i>“Pig vaccination as a tool for significant reduce of antibiotics”</i>
3:55 – 5:00	Discussion
5:00 – 5:30	Closing remarks
Schloßsaal	Plenary session
5:30	End of session



Working group 3: Identifying global priority pathogens for R&D needs for AMR

Room: *Schloßsaal*

Morning session

WHO is committed to advance towards a global development and stewardship framework to support the development, control, distribution and appropriate use of new antimicrobial medicines, diagnostic tools, vaccines and other interventions, while preserving existing antimicrobial medicines and promoting affordable access to existing and new antimicrobial medicines and diagnostic tools worldwide. The identification of a list of priority pathogens (PPL) and resistance mechanisms of greatest concern for global AMR represents an important contribution to this framework.

The session gives the opportunity to present and discuss the approach and methodology of developing a global R&D priority pathogens list for AMR and the next steps forward.

9:00 – 9:30	Welcome coffee and registration
9:30 – 10:00	Welcome and opening session
Schloßsaal	Minister Hermann Gröhe, Federal Ministry of Health (BMG), Germany Federal Councillor Alain Berset, Federal Department of Home Affairs, Switzerland
10:00 – 10:10	Speaker
	Dr. Benjamin Grosch, Boston Consulting Group (BCG), Partner & Managing Director, Germany <i>“GUARD initiative: Enhancing Research and Development of Antibiotics in Science and Industry”</i>
Schloßsaal	Working group 3: Identifying global priority pathogens for R&D needs for AMR
	Chair: Dr. Manica Balasegaram, Global Antibiotic Research & Development (GARDP), Director, Switzerland
10:10 – 10:40	Speaker
	Prof. Dr. Martin Mielke, Robert Koch-Institute, Head of Department, Germany <i>“R & D needs – Priority pathogens”</i>
10:40 – 11:00	Speaker
	Dr. Dominique Monnet, European Centre for Disease Prevention and Control (ARHAI), Head of Programme, Sweden <i>“Identifying global priority pathogens for R&D needs for antimicrobial resistance”</i>
11:00 – 11:05	Coffee break



11:05 – 12:05 Speaker

Dr. Nicola Magrini, World Health Organization (WHO), Switzerland and
Prof. Dr. Evelina Tacconelli, University Hospital Tübingen, Germany
*“Development of a global R&D Priority Antimicrobial Resistant
Pathogen List”*

12:05 – 01:00 Panel Discussion on methodology and potential use of PPL

Prof. Dr. Yehuda Carmeli, Tel Aviv University, Israel

Prof. Dr. Kevin Outterson, Boston University, USA

James Anderson, GSK, Director European Partnerships, UK

Prof. Dr. Martin Mielke, Robert Koch-Institute, Head of Department,
Germany

Dr. Dominique Monnet, European Centre for Disease Prevention and
Control, Head of Programme, Sweden

Prof. Dr. Evelina Tacconelli, University Hospital Tübingen, Germany

Dr. Nicola Magrini, World Health Organization (WHO), Switzerland

1:00 – 2:00 Lunch break



Working group 4: Global Antibiotic Research and Development Partnership (GARDP): A Roadmap to stimulating innovations in the AMR R&D Ecosystem

Room: *Schloßsaal*

Afternoon session

The Global Antibiotic Research and Development Partnership is a joint Drugs for Neglected Diseases initiative (DNDi)/World Health Organization and was set up as a result of the Global Action Plan on Antimicrobial Resistance. Currently incubated and hosted by DNDi, GARDP is a nonprofit R&D initiative, set up to meet critical and global unmet patient needs by developing new antibiotic treatments, embedding sustainable access (innovation, stewardship, and access) into all R&D activities, and testing incentive and financing mechanisms that are conducive to this.

This session aims to provide a state-of-affairs of GARDP and its initial projects, review approaches to sustainable access, and explore complementarity of approaches to priority setting.

Schloßsaal	Working group 4: A Roadmap to stimulating innovations in the AMR R&D Ecosystem
	Chair: Prof. Dr. Herman Goossens, University of Antwerp, Belgium
2:00 – 3:00	Speakers
	Dr. Line Matthiessen, Head of Unit, European Commission <i>“Overview of EU and EC efforts to stimulate Antimicrobial R&D for Global Impact”</i>
	Dr. Manica Balasegaram, Global Antibiotic Research & Development (GARDP), Director, Switzerland <i>“Filling a critical role in the current antibiotic treatment landscape – General Overview of the Global Antibiotic R&D Partnership”</i>
	Dr. Jean-Pierre Paccaud, Global Antibiotic Research & Development (GARDP), Business Strategy Director, Switzerland <i>“Cross-Cutting Research Endeavours: Drug Combination Platform & Antibiotic Memory Recovery initiative (AMRi)”</i>
3:00 – 3:30	Prof. Dr. Mike Sharland, St George's University, UK and Teodora Wi, World Health Organization (WHO), Switzerland <i>“Global disease approaches: Neonatal Sepsis”</i>
	Moderated Q&A
	Moderator: Dr. Kamini Walia, Indian Council of Medical Research, India <i>“Disease Priorities and Scientific Strategy”</i>



3:30 – 3:45	Speakers
	Dr. Peter Beyer, World Health Organization (WHO), Coordinator a.i., Switzerland <i>“A global development and stewardship framework for AMR”</i>
	Prof. Dr. Marc Mendelson, University of Cape Town, Head of Division, South Africa <i>“How to concretely address sustainable access and stewardship within R&D”</i>
3:45 – 4:00	Moderated Q&A
	Moderator: Dr. Kamini Walia, Indian Council of Medical Research, India <i>“Sustainable Access and Stewardship”</i>
4:00 – 4:40	Panel Discussion
	Chair: Prof. Dr. Herman Goossens, University of Antwerp, Belgium
	Dr. Nicola Magrini, World Health Organization (WHO), Switzerland
	Dr. Anban Pillay, National Department of Health, Deputy Director-General, South Africa
	Dr. Mercedes Tatay, Médecins Sans Frontières (MSF), International Medical Secretary, Switzerland
	Prof. Dr. Kevin Outterson, Boston University, USA
	Dr. Tim Jinks, Wellcome Trust, UK
	Dagmar Reitenbach, Federal Ministry of Health, Global Health Team, Germany
	<i>R&D priority setting is currently a key theme in AMR. In R&D, treatments need to be developed not just to treat specific diseases and pathogens, but also syndromes and patient populations. This discussion aims to explore the complementarity of these approaches, in addition to provide insight into how countries and funders can approach this.</i>
4:40 – 4:55	Moderated Q&A
	Moderator: Dr. Kamini Walia, Indian Council of Medical Research, India
4:55 – 5:00	Conclusions
5:00 – 5:30	Closing remarks
Schloßsaal	Plenary session
5:30	End of session